Company intelligence / Profile preview

Nimbus Therapeutics

Boston, Massachusetts, United Statesnimbustx.com ↗

Ownership: Private
Employees: ~22
Development stage: Phase 1

Overview

Nimbus has a clinical-stage pipeline highlighted by WRN inhibitor NDI-219216 currently in Phase 1/2 trials for advanced solid tumors. Past programs have successfully demonstrated proof of mechanism and have been acquired by major pharmaceutical companies, including ACC inhibitors by Gilead and TYK2 inhibitors by Takeda, both now in late-stage clinical trials or post-acquisition development[1][4][6].

Therapeutic areas: EndocrinologyRheumatologyMetabolic DisordersDermatologyOncology
Modalities: Small moleculeProteolysis-targeting chimera therapy
Industry: Biotech

Drug pipeline

1 asset

NDI-219216

Phase 1

Indications: MSI-H tumors

Partnerships

Eli LillyGileadTakeda

Beyond the preview

Go deeper on Nimbus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nimbus Therapeutics.

Explore the full profile